Central Illinois, Illinois

HomeIllinoisCentral Illinois

Email Ryan R. Bradley
Ryan R. Bradley
Ryan R. Bradley
Attorney • (217) 337-1400

Xarelto Mass Tort Lawsuits on the Rise Calling into Question Many Blood Thinners


Seemingly every month there is a new mass tort lawsuits against a pharmaceutical company for false advertising, serious side effects, and other issues that have harmed patients.  We have all seen the horrible and cheesy ads on daytime and evening television and the tasteless pay-per-click onslaught each time we log on to Google.  Don’t fall victims to these ads by the way.  We will discuss more about that later.

Though not new news, one of the most prevalent and heavily advertised is Rivaroxaban (brand name Xarelto), a new-generation anticoagulant—a blood thinner—used to reduce the risk of blood clots and strokes.  Xarelto, and other blood thinners such as Pradaxa, were designed to take the place of age-old favorite Coumadin. Approved by the U.S. Food and Drug Administration (FDA) in 2011, manufactured by Janssen Pharmaceuticals, sold by Johnson & Johnson, and overseen by Bayer, Xarelto’s manufacturers assert the drug is easier to use than the older standard, warfarin (brand name Coumadin).  The efficacy of the drugs does not differ greatly, but the dosing is much easier to control and monitor than warfarin.

Because of a lack of antidote, (warfarin can be reversed with Vitamin K) Xarelto faces accusations of being responsible for myriad potentially serious medical problems such as:

  • Uncontrollable brain, eye, and gastrointestinal hemorrhaging
  • Strokes
  • Epidural hematomas
  • Deep vein thrombosis
  • Adrenal bleeding
  • Decrease in hemoglobin
  • Pulmonary embolisms
  • Death

Hemorrhaging is particularly worrisome because even minor injuries such as cuts can result in uncontrolled bleeding; especially with a lack of an antidote to counter the drug’s blood-thinning effects.

Xarelto Lawsuits

As many as 7,000 complaints against Xarelto have come to light, with plaintiffs alleging that the drug is responsible for serious and/or fatal hemorrhaging because the patient’s blood cannot properly clot. Additional accusations surround the company’s failure to adequately warn patients that Xarelto has no antidote, subsequently increasing patients’ potential for serious and/or fatal bleeding problems.

The FDA warned Xarelto’s manufacturers in 2013 that their advertisements were misleading as they minimized potential risks, and additional accusations arose that the company deliberately used misleading tactics to advertise, market, and sell its product. Further, Janssen faces accusations of using false clinical data promoting the drug as more effective than it really was and—even more egregious—publishing incomplete and misleading data in respected medical journals such as the New England Journal of Medicine.

Recently, a Louisiana judge extended the filing deadline for plaintiffs an additional ninety days because of the sheer volume of complaints.

Xarelto earned nearly $2 billion in the U.S. alone in 2015.

For more information, or if you or a loved one has been harmed by Xarelto or any other medication, please contact us.

Leave a Comment

Have an opinion? Please leave a comment using the box below.

For information on acceptable commenting practices, please visit Lifehacker's guide to weblog comments. Comments containing spam or profanity will be filtered or deleted.

Illinois Plaintiffs Lawyer by Koester & Bradley